[go: up one dir, main page]

MX2021004741A - Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo. - Google Patents

Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.

Info

Publication number
MX2021004741A
MX2021004741A MX2021004741A MX2021004741A MX2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A MX 2021004741 A MX2021004741 A MX 2021004741A
Authority
MX
Mexico
Prior art keywords
compound
same
aminopeptidase
inhibitors
pharmaceutical compositions
Prior art date
Application number
MX2021004741A
Other languages
English (en)
Other versions
MX390718B (es
Inventor
Catherine Llorens-Cortes
Yannick Marc
Fabrice Balavoine
Delphine Compere
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of MX2021004741A publication Critical patent/MX2021004741A/es
Publication of MX390718B publication Critical patent/MX390718B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/306Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3258Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3264Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653Five-membered rings
    • C07F9/65306Five-membered rings containing two nitrogen atoms
    • C07F9/65312Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención actual se refiere a un nuevo compuesto, a una composición que lo comprende, a métodos para preparar el compuesto y al uso de este compuesto en terapia. En particular, la invención actual se refiere a un compuesto que es útil en el tratamiento y prevención de hipertensión arterial primaria y secundaria, accidente cerebrovascular, isquemia miocárdica, insuficiencia cardíaca y renal, infarto de miocardio, enfermedad vascular periférica, proteinuria diabética, síndrome X y glaucoma.
MX2021004741A 2018-10-26 2019-10-25 Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo. MX390718B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306396 2018-10-26
PCT/EP2019/079229 WO2020084131A1 (en) 2018-10-26 2019-10-25 Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same

Publications (2)

Publication Number Publication Date
MX2021004741A true MX2021004741A (es) 2022-03-16
MX390718B MX390718B (es) 2025-03-21

Family

ID=64267736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004741A MX390718B (es) 2018-10-26 2019-10-25 Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.

Country Status (15)

Country Link
US (1) US11192907B2 (es)
EP (1) EP3870591A1 (es)
JP (1) JP7051009B2 (es)
KR (1) KR102380042B1 (es)
CN (1) CN113166182A (es)
AR (1) AR116853A1 (es)
AU (1) AU2019365119B2 (es)
BR (1) BR112021007116A2 (es)
CA (1) CA3112851C (es)
EA (1) EA202191150A1 (es)
IL (1) IL282591B (es)
MX (1) MX390718B (es)
TW (1) TW202029962A (es)
WO (1) WO2020084131A1 (es)
ZA (1) ZA202103580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191151A1 (ru) * 2018-10-26 2021-07-15 Квантум Дженомикс Новые аминофосфиновые производные в качестве ингибиторов аминопептидазы а
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素-血管收縮素系統阻斷劑之醫藥組合物
CN115385789B (zh) * 2022-09-19 2024-06-04 安徽大学 一种4-氧代丁酸甲酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) * 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
ES2369256T3 (es) * 2000-06-26 2011-11-28 Helen Of Troy Limited Sistema de lámpara recargable.
AR058296A1 (es) * 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
US20080146524A1 (en) 2006-12-14 2008-06-19 Solvay Pharmaceuticals B.V. Selective inhibitors of neurotensin degrading enzymes
FR2934267B1 (fr) * 2008-07-23 2010-08-13 Pharmaleads Derives aminophosphiniques utiles dans le traitement de la douleur
EA202191151A1 (ru) 2018-10-26 2021-07-15 Квантум Дженомикс Новые аминофосфиновые производные в качестве ингибиторов аминопептидазы а

Also Published As

Publication number Publication date
US11192907B2 (en) 2021-12-07
IL282591B (en) 2022-08-01
KR102380042B1 (ko) 2022-03-28
EP3870591A1 (en) 2021-09-01
AU2019365119B2 (en) 2021-07-29
MX390718B (es) 2025-03-21
EA202191150A1 (ru) 2021-07-15
BR112021007116A2 (pt) 2021-07-20
AU2019365119A1 (en) 2021-04-15
JP7051009B2 (ja) 2022-04-08
WO2020084131A1 (en) 2020-04-30
KR20210079336A (ko) 2021-06-29
US20210309678A1 (en) 2021-10-07
CA3112851C (en) 2023-01-24
CA3112851A1 (en) 2020-04-30
AR116853A1 (es) 2021-06-23
IL282591A (en) 2021-06-30
JP2021535189A (ja) 2021-12-16
TW202029962A (zh) 2020-08-16
ZA202103580B (en) 2022-08-31
CN113166182A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
MX2021004741A (es) Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
MX2025003398A (es) Nuevo compuesto tetraheterociclico
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA202190749A1 (ru) Способы комбинированной терапии
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MX2020010805A (es) Inhibidores de bcl6.
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MY209034A (en) Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
SA521431279B1 (ar) D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2021004728A (es) Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a.
MY187899A (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor